Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

v2.4.0.6
Condensed Balance Sheets (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2013
Dec. 31, 2012
Current assets:    
Cash $ 17,606 $ 18,102
Receivables 4,094 4,646
Prepaid expenses and other current assets 265 687
Total current assets 21,965 23,435
Property and equipment, net 1,567 1,392
Total assets 23,532 24,827
Current liabilities    
Accounts payable 5,039 3,767
Accrued clinical trials expenses 1,390 532
Other accrued liabilities 427 219
Deferred contract revenue 10,625 14,375
Current portion of long-term debt 2,500 2,500
Total current liabilities 19,981 21,393
Warrant liability 6,599 8,240
Royalty liability   8,962
Long-term debt, net of discount   9,360
Total liabilities 26,580 47,955
Commitments and contingencies      
Stockholders' deficit    
Common stock, at amounts paid-in 279,560 265,986
Additional paid-in capital 21,519 21,014
Accumulated deficit (304,127) (310,128)
Total stockholders' deficit (3,048) (23,128)
Total liabilities and stockholders' deficit $ 23,532 $ 24,827